Top

20-02-2018 | Granulomatosis with polyangiitis | Article

Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes

Journal: Clinical Rheumatology

Authors: Mara Felicetti, Diego Cazzador, Roberto Padoan, Alfonso Luca Pendolino, Chiara Faccioli, Ennio Nardello, Alvise Berti, Marina Silvestrini, Giuseppe Paolazzi, Giuliano Brunori, Elisabetta Zanoletti, Enzo Emanuelli, Alessandro Martini, Franco Schiavon

Publisher: Springer London

Abstract

Ear, nose and throat (ENT) manifestations in granulomatosis with polyangiitis (GPA) represent the most frequent symptoms at disease onset. The aim of the study was to analyse ENT involvement at diagnosis, as well as how it could influence relapse rate, mortality and disease severity. A retrospective non-controlled cohort study was performed including all consecutive diagnosed GPA from 1996 to 2016 in two rheumatology centres of Northern Italy, focusing particularly on ENT presenting signs and symptoms at baseline. Eighty-nine patients (48.3% females) with new onset GPA were evaluated. They were mostly Caucasian (97.7%), middle aged (mean 54.5 years) and more frequently anti-neutrophil cytoplasmic antibodies (ANCA) positive (78.6%) with PR3 specificity (81.4%). At diagnosis, ENT involvement was reported in 71.9% patients, second only to systemic symptoms. These patients were significantly younger at disease onset (0.013), with less frequent renal involvement (0.014) irrespectively to ANCA status, but with significantly higher Vasculitis Damage Index (VDI) (0.001). The most frequent ENT manifestation was sinonasal involvement (58.4%, 73% of which with nasal inflammation/chronic sinusitis and 48% with nasal crusting), while otologic involvement (mainly otitis media/otomastoiditis) was observed in 34.8%. ENT-GPA patients presented a higher survival rate at 5 years (98.1 vs 77.7%, 0.049), and ENT involvement resulted to be an independent predictor of better outcome (OR 0.37, 95% CI 0.2–0.8, 0.019). Our data confirms that ENT involvement is not only one of the key clinical features of GPA, but also could point out a milder GPA subset with lower renal involvement and lower mortality rate, irrespectively to ANCA status.

Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DRW, Jennette JC, Kallenberg CGM, Luqmani R, Mahr AD, Matteson EL, Merkel PA, Specks U, Watts RA, American College of Rheumatology, American Society of Nephrology, European League Against Rheumatism (2011) Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum 63(4):863–864. https://doi.org/10.1002/art.30286 CrossRefPubMed

Holle JU, Laudien M, Gross WL (2010) Clinical manifestations and treatment of Wegener’s granulomatosis. Rheum Dis Clin N Am 36(3):507–526. https://doi.org/10.1016/j.rdc.2010.05.008 CrossRef

Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA (1996) The epidemiology of Wegener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39(1):87–92. https://doi.org/10.1002/art.1780390112 CrossRefPubMed

Mohammad AJ, Jacobsson LTH, Mahr AD, Sturfelt G, Segelmark M (2007) Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 46(8):1329–1337. https://doi.org/10.1093/rheumatology/kem107 CrossRef

Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CGM, Merkel PA, Raspe H, Salvarani C, Scott DGI, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, for the European Vasculitis Study Group (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317. https://doi.org/10.1136/ard.2008.088096 CrossRefPubMed

Tsuzuki K, Fukazawa K, Takebayashi H, Hashimoto K, Sakagami M (2009) Difficulty of diagnosing Wegener’s granulomatosis in the head and neck region. Auris Nasus Larynx 36(1):64–70. https://doi.org/10.1016/j.anl.2008.02.003 CrossRefPubMed

Garcia-Porrua C, Amor-Dorado JC, Gonzalez-Gay MA (2001) Unilateral submandibular swelling as unique presentation of Wegener’s granulomatosis. Rheumatology (Oxford) 40(8):953–954. https://doi.org/10.1093/rheumatology/40.8.953 CrossRef

Wiik A (2002) Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford) 41(5):481–483. https://doi.org/10.1093/rheumatology/41.5.481 CrossRef

Jennings CR, Jones NS, Dugar J, Powell RJ, Lowe J (1998) Wegener’s granulomatosis—a review of diagnosis and treatment in 53 subjects. Rhinology 36(4):188–191PubMed

10.

McDonald TJ, DeRemee RA (1993) Head and neck involvement in Wegener’s granulomatosis (WG). Adv Exp Med Biol 336:309–313. https://doi.org/10.1007/978-1-4757-9182-2_49 CrossRefPubMed

11.

Martinez Del Pero M, Rasmussen N, Chaudhry A, Jani P, Jayne D (2013) Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener’s). Eur Arch Otorhinolaryngol 270(1):345–354. https://doi.org/10.1007/s00405-012-2110-8 CrossRefPubMed

12.

Hernández-Rodríguez J, Hoffman GS, Koening CL (2010) Surgical interventions and local therapy for Wegener’s granulomatosis. Curr Opin Rheumatol 22(1):29–36. https://doi.org/10.1097/BOR.0b013e328333e9e9 CrossRefPubMed

13.

Ono N, Niiro H, Ueda A, Sawabe T, Nishizaka H, Furugo I, Yoshizawa S, Yoshizawa S, Tsukamoto H, Kiyohara C, Tada Y, Horiuchi T (2015) Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan. Rheumatol Int 35(3):555–559. https://doi.org/10.1007/s00296-014-3106-z CrossRefPubMed

14.

Schirmer JH, Wright MN, Herrmann K et al (2016) Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol (Hoboken, N.J.) 68(12):2953–2963CrossRef

15.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227. https://doi.org/10.1136/ard.2006.054593 CrossRefPubMed

16.

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68(12):1827–1832. https://doi.org/10.1136/ard.2008.101279 CrossRefPubMed

17.

Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage COS, Adu D (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380. https://doi.org/10.1002/art.1780400222 CrossRefPubMed

18.

Levey AS, Stevens LA, Schmid CH, Zhang Y(L), Castro AF III, Feldman HI, Kusek JW, Eggers P, van Lente F, Greene T, Coresh J, for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 CrossRefPubMedPubMedCentral

19.

Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204CrossRefPubMedPubMedCentral

20.

Hauer HA, Bajema IM, van Houwelingen HC et al (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61(1):80–89. https://doi.org/10.1046/j.1523-1755.2002.00089.x CrossRefPubMed

21.

Rahmattulla C, de Lind van Wijngarden RA, Berden AE et al (2015) Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford) 54(5):899–907. https://doi.org/10.1093/rheumatology/keu357 CrossRef

22.

Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488–498. https://doi.org/10.7326/0003-4819-116-6-488 CrossRefPubMed

23.

Sproson EL, Jones NS, Al-Deiri M, Lanyon P (2007) Lessons learnt in the management of Wegener’s granulomatosis: long-term follow-up of 60 patients. Rhinology 45(1):63–67PubMed

24.

McDonald TJ, DeRemee RA (1983) Wegener’s granulomatosis. Laryngoscope 93(2):220–231CrossRefPubMed

25.

Wojciechowska J, Krajewski W, Krajewski P, Kręcicki T (2016) Granulomatosis with polyangiitis in otolaryngologist practice: a review of current knowledge. Clin Exp Otorhinolaryngol 9(1):8–13. https://doi.org/10.21053/ceo.2016.9.1.8 CrossRefPubMedPubMedCentral

26.

Rahne T, Clauß F, Plontke SK, Keyßer G (2017) Prevalence of hearing impairment in patients with rheumatoid arthritis, granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis), or systemic lupus erythematosus. Clin Rheumatol 36(7):1501–1510. https://doi.org/10.1007/s10067-017-3651-4 CrossRefPubMed

27.

Gottschlich S, Ambrosch P, Kramkowski D, Laudien M, Buchelt T, Gross WL, Hellmich B (2006) Head and neck manifestations of Wegener’s granulomatosis. Rhinology 44(4):227–233PubMed

28.

Kornblut AD, Wolff SM, deFries HO, Fauci AS (1980) Wegener’s granulomatosis. Laryngoscope 90(9):1453–1465. https://doi.org/10.1288/00005537-198009000-00005 CrossRefPubMed

29.

Langford CA, Sneller MC, Hallahan CW, Hoffman GS, Kammerer WA, Talar-Williams C, Fauci AS, Lebovics RS (1996) Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 39(10):1754–1760. https://doi.org/10.1002/art.1780391020 CrossRefPubMed

30.

Pavone L, Grasselli C, Chierici E, Maggiore U, Garini G, Ronda N, Manganelli P, Pesci A, Rioda WT, Tumiati B, Pavesi G, Vaglio A, Buzio C, Secondary and Primar Vasculitides (Se.Pri.Va) Study Group (2006) Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 33(7):1299–1306PubMed

31.

Bligny D, Mahr A, Le Toumelin P, Mouthon L, Guillevin L (2004) Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 51(1):83–91. https://doi.org/10.1002/art.20082 CrossRefPubMed

32.

Mohammad AJ, Jacobsson LTH, Westman KWA, Sturfelt G, Segelmark M (2009) Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 48(12):1560–1565. https://doi.org/10.1093/rheumatology/kep304 CrossRef

33.

Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64(10):3452–3462. https://doi.org/10.1002/art.34562 CrossRefPubMedPubMedCentral

34.

Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33(2 Suppl 89):S-77–S-83

35.

Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R (2016) Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol 35(7):1805–1816. https://doi.org/10.1007/s10067-016-3195-z CrossRefPubMed

36.

Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, Merkel PA, Pagnoux C, Rasmussen N, Westman K, Jayne DRW, for the French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS) (2013) Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 72(6):1003–1010. https://doi.org/10.1136/annrheumdis-2012-201750 CrossRefPubMed

37.

Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, for the European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494. https://doi.org/10.1136/ard.2010.137778 CrossRefPubMed

38.

Wallace ZS, Lu N, Unizony S, Stone JH, Choi HK (2016) Improved survival in granulomatosis with polyangiitis: a general population-based study. Semin Arthritis Rheum 45(4):483–489. https://doi.org/10.1016/j.semarthrit.2015.07.009 CrossRefPubMed

Medicine Matters Rheumatology

Abstract